Fort LP’s Charles River Laboratories CRL Stock Holding History

Fort LP’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-63	Closed	-$9K	–	445
2019 Q1	$9K	Sell	63 -176	-74%	-$23.1K	﹤0.01%	427
2018 Q4	$27K	Buy	+239	New	+$29.9K	0.01%	375

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Fort LP's CRL Position: Q2 2019 in Review

Fort LP sold out of Charles River Laboratories (CRL) in Q2 2019, closing a stake of 63 shares — an estimated $9K sold.

Fort LP first reported a position in CRL in Q4 2018 and held it in 2 quarters. The position peaked at $27K in Q4 2018. 405 funds tracked by Wall St. Rank hold CRL as of Q2 2019.

Fort LP reported no remaining Charles River Laboratories position as of Q2 2019 after selling out during the quarter.
Fort LP sold 63 Charles River Laboratories shares in Q2 2019, an estimated $9K.
Fort LP first reported a position in Charles River Laboratories in Q4 2018 and held it in 2 quarters.
Fort LP's Charles River Laboratories position peaked at $27K in Q4 2018.
405 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2019.

Based on Fort LP's 13F filing for Q2 2019, filed 13 Aug 2019.